Part of the ICU Emergencies Hub — browse every related guide in one place.
AKI is defined by the KDIGO (Kidney Disease Improving Global Outcomes) criteria as ANY of the following:
| Stage | Creatinine Criteria | Urine Output |
|---|---|---|
| Stage 1 | 1.5–1.9x baseline within 7 days OR ≥0.3 mg/dL rise within 48 hr | <0.5 mL/kg/hr for 6–12 hr |
| Stage 2 | 2.0–2.9x baseline | <0.5 mL/kg/hr for ≥12 hr |
| Stage 3 | ≥3.0x baseline OR creatinine ≥4.0 mg/dL OR initiation of renal replacement therapy | <0.3 mL/kg/hr for ≥24 hr OR anuria for ≥12 hr |
| Category | Mechanism | Common Causes | Key Indicators |
|---|---|---|---|
| Prerenal AKI (~55%) | Decreased renal perfusion without intrinsic kidney damage; kidneys are functionally intact but under-perfused; REVERSIBLE with fluid resuscitation | Hypovolemia (dehydration, hemorrhage, burns), cardiogenic shock, septic shock, hepatorenal syndrome, NSAIDs/ACE inhibitors reducing GFR, renal artery stenosis | BUN/Cr ratio >20:1; urine Na <20 mEq/L; urine specific gravity >1.020; FENa <1%; concentrated urine (kidneys trying to conserve); responds to fluid challenge |
| Intrinsic (Intrarenal) AKI (~40%) | Direct damage to renal parenchyma (tubules, glomeruli, interstitium, vasculature) | ATN (acute tubular necrosis — most common intrinsic cause; ischemic or nephrotoxic); contrast nephropathy; aminoglycoside toxicity; glomerulonephritis; interstitial nephritis (NSAIDs, penicillin); rhabdomyolysis | BUN/Cr ratio <15:1 (creatinine rises proportionally more); urine Na >40 mEq/L (kidneys can't reabsorb); FENa >2%; muddy brown casts (ATN); does NOT respond to fluids alone |
| Postrenal AKI (~5%) | Obstruction to urine flow from the collecting system outward; relief of obstruction is curative | BPH (most common in elderly men), kidney stones, tumors (cervical, prostate, bladder), clots, strictures, neurogenic bladder, inadvertent ureteral ligation during surgery | Bilateral hydronephrosis on ultrasound; symptoms of obstruction (difficulty voiding, distended bladder); immediate improvement after catheterization or stent placement |
| Complication | Treatment |
|---|---|
| Hyperkalemia | Calcium gluconate (cardiac stabilization); insulin + D50 (shift K+ into cells); sodium bicarbonate; kayexalate or patiromer (excretion); dialysis if >6.5 or symptoms |
| Fluid overload | Fluid restriction; loop diuretics (furosemide) if patient still makes urine; dialysis if refractory |
| Metabolic acidosis | Treat underlying cause; sodium bicarbonate if pH <7.10 or HCO3 <10; dialysis |
| Uremia | Protein restriction (controversial); dialysis is definitive for symptomatic uremia |
| Hypertension | Antihypertensives (avoid ACE inhibitors/ARBs acutely — reduce GFR); fluid removal via dialysis or diuretics |
| Nephrotoxin | Mechanism | Nursing Action |
|---|---|---|
| NSAIDs (ibuprofen, ketorolac, naproxen) | Inhibit prostaglandin-mediated renal afferent arteriole dilation → reduce GFR; especially dangerous in low-perfusion states | AVOID in AKI or at-risk patients; hold if creatinine rising; discontinue and use acetaminophen instead |
| ACE inhibitors / ARBs (lisinopril, losartan) | Block angiotensin II-mediated efferent arteriole constriction → reduce GFR in renovascular/volume-depleted states | Hold in acute AKI, sepsis, severe dehydration, or bilateral renal artery stenosis; restart when hemodynamically stable |
| IV Contrast dye | Direct tubular toxicity + renal vasoconstriction; highest risk in CKD, diabetes, dehydration | Pre-hydrate with IV NS before and after contrast; minimize contrast volume; use iso-osmolar contrast; hold metformin 48 hr |
| Aminoglycosides (gentamicin, tobramycin) | Direct tubular toxicity; accumulate in renal cortex; dose-dependent; non-oliguric ATN | Once-daily dosing preferred (less tubular accumulation); monitor trough levels; avoid concurrent nephrotoxins; assess renal function frequently; hydration |
| Vancomycin | Nephrotoxicity especially with concurrent aminoglycosides or contrast; tubular toxicity | Monitor vancomycin AUC/MIC (AUC-guided dosing replaces trough monitoring per 2020 ASHP guidelines); avoid concurrent aminoglycosides; optimize hydration |
Get The ICU Notebook Newsletter
Clinical tools and career insights for ICU nurses. One email per week, no fluff.
Yes, send it freeNo spam. Unsubscribe any time.